Newsletter

You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. You can also unsubscribe by going to http://listserv.otcjournal.com and entering your email address there while selecting unsubscribe.


OTC Journal Newsletter
June 22, 1999	Volume II, Issue 26

Email : info@otcjournal.com
URL : http://www.otcjournal.com

To OTC Journal Members:

From time to time we try to bring you information on our profiled companies at a time which the stocks have retreated to a level where we feel they are an excellent value. Our April profile, US Microbics (OTC BB: BUGS) is a stock worth reviewing in its current trading range.

We released our profile on April 10th when the stock was in the $4.50 range. Today, the stock closed at $3.25 on light volume.

We visited the Company last week, and we believe that US Microbics is on track to achieve some major milestones this year. If you did not read our original profile, now would be a good time to do so. You can read the original profile by Clicking Here. You can also find all the due diligence you might want on the Company at their corporate web site at www.bugsatwork.com. Click on the Investor Info Section for financial information.

We were interested in learning more about the relationship with Builder's Referral Corporation which was announced of May 25th (click here to read press release). Builder's Referral has become US Microbics marketing arm for the BioRaptor(tm) machine to contractors that service both contaminated private and public properties, and Military Bases. If you would like to learn more about the BioRaptor(tm) and see a picture of it, click here.

We interviewed Jeb Hook, the President of Builder's Referral this morning. He informed us that on any given week, there are 8 to 10 potential customers attending a weekly seminar at the Company, and then going to view the operating BioRaptor(tm) machine in Rancho SantaFe, California.

The potential customers include Military Officials, Contractors, and Public Officials. Mr. Hook also told us that after one month of preliminary sales work, he felt comfortable that Builder's Referral would be able to meet or exceed its obligation to get 100 BioRaptors(tm) in the field in the first three years. Each BioRaptor(tm), operating at 80% capacity, represents about $3 million in annual sales to US Microbics. This equates to a potential market of $300 million.

Mr. Hook also told us that Builder's Referral estimates the size of the market for these products to be approximately $700 billion per year.

After spending some time at the Company last week, we were excited about their prospects. Look for some exciting fundamental developments from US Microbics (OTC BB: BUGS) which we will bring to you in the near future.

Links to Free Downloads

Disclaimer

The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. All statements and expressions are the sole opinions of the editors and are subject to change without notice. This profile is neither an offer nor solicitation to buy or sell any securities mentioned. This newsletter is owned by SSP Management, Inc, a wholly owned subsidiary of 1st Net Technologies, Inc ("1st Net"). While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with which they are affiliated, may own stock in and have other financial dealings with the companies who appear in the publication. To that degree, this newsletter should not be regarded to be an independent publication. SSP Management has received the following compensation for representing US
Microbics for a period of one year: $50,000 in cash, and 50,000 options convertible into restricted stock,
exercisable at $1 per share. In a related transaction, SSP Management intends to exercise its option by signing a
promissory note to US Microbics for $50,000. The OTCjournal.com critiques may contain forward looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.